December 15, 2016
Canada's Cancer Research Society has announced the appointment of Max Fehlmann as its new President and Chief Executive Officer, effective January 16, 2017. Fehlmann founded the NEOMED Institute - a non-profit organization bridging the gap between academic innovations and the needs of the industry - and was its president since 2012. Before NEOMED, Fehlmann founded the Consortium Québécois pour la Découverte du Médicament (CQDM) in 2008, a public-private non-profit organization financing precompetitive research in drug discovery. He is a member of the Scientific Advisory Board of OncoAge in Nice, France, a member of the Board of Directors of RSSPQ in Montreal, and a member of the Board of Directors of CQDM, Montreal.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.